Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.750 +0.100 (+3.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Second Quarter 2023 Financial Results on August 1
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed... 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports First Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.